臨床外科78巻7号

2023年07月発行

特集 術後急変！—予知・早期発見のベストプラクティス 各論1：各種ショックが起こってしまったときの初療

敗血症性ショック

著者： 石橋勇輔¹ 辻本広紀¹ 上野秀樹¹

所属機関： ¹防衛医科大学校外科

ページ範囲：P.801 - P.805

【ポイント】
◆敗血症性ショックの診断はSepsis-3の定義に従いSOFA，qSOFAを用いて迅速に行う．
◆術後敗血症性ショックの治療の大原則は循環・呼吸動態の管理，感染源の同定とその制御であり，抗菌薬加療の役割は大きい．
◆敗血症性ショックへのPMX-DHP療法の有用性に関しては，今後の検討課題である．

参考文献

1）Singer M, Deutschman CS, Seymour CW, et al：The Third International Consensus Definitions for Sepsis and Septic Shock（Sepsis-3）. JAMA 315：801-810, 2016

2）Physicians ACoC, Committee SoCCMCC：American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference：definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20：864-874, 1992

3）Kaukonen KM, Bailey M, Pilcher D, et al：Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 372：1629-1638, 2015

4）Levy MM, Fink MP, Marshall JC, et al：2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31：1250-1256, 2003

5）Vincent J L, Moreno R, Takala J, et al：The SOFA（Sepsis-related Organ Failure Assessment）score to describe organ dysfunction/failure. Springer-Verlag, 1996.

6）Evans L, Rhodes A, Alhazzani W, et al：Surviving Sepsis Campaign：International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 49：e1063-e1143, 2021

7）Evans L, Rhodes A, Alhazzani W, et al：Surviving sepsis campaign：international guidelines for management of sepsis and septic shock 2021. Intensive care medicine 47：1181-1247, 2021

8）Rhodes A, Evans LE, Alhazzani W, et al：Surviving Sepsis Campaign：International Guidelines for Management of Sepsis and Septic Shock：2016. Crit Care Med 45：486-552, 2017

9）Investigators A, Group tACT：Goal-directed resuscitation for patients with early septic shock. N Engl J Med 371：1496-1506, 2014

10）Investigators P：A randomized trial of protocol-based care for early septic shock. N Engl J Med 370：1683-1693, 2014

11）Mouncey PR, Osborn TM, Power GS, et al：Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 372：1301-1311, 2015

12）日本集中治療医学会，日本救急医学会：日本版敗血症診療ガイドライン2020．日集中医誌28：10-400，2021

13）Lamontagne F, Meade MO, Hébert PC, et al：Higher versus lower blood pressure targets for vasopressor therapy in shock：a multicentre pilot randomized controlled trial. Intensive Care Med 42：542-550, 2016

14）Asfar P, Meziani F, Hamel JF, et al：High versus low blood-pressure target in patients with septic shock. N Engl J Med 370：1583-1593, 2014

15）Fan E, Brodie D, Slutsky AS：Acute respiratory distress syndrome：advances in diagnosis and treatment. JAMA 319：698-710, 2018

16）Chu DK, Kim LH, Young PJ, et al：Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy（IOTA）：a systematic review and meta-analysis. Lancet 391：1693-1705, 2018

17）Phua J, Ngerng W, See K, et al：Characteristics and outcomes of culture-negative versus culture-positive severe sepsis. Critical Care 17：R202, 2013

18）Charles PE, Tinel C, Barbar S, et al：Procalcitonin kinetics within the first days of sepsis：relationship with the appropriateness of antibiotic therapy and the outcome. Critical Care 13：1-11, 2009

19）Dellinger RP, Bagshaw SM, Antonelli M, et al：Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level：the EUPHRATES randomized clinical trial. JAMA 320：1455-1463, 2018

20）Cruz DN, Antonelli M, Fumagalli R, et al：Early use of polymyxin B hemoperfusion in abdominal septic shock：the EUPHAS randomized controlled trial. JAMA 301：2445-2452, 2009

21）Payen DM, Guilhot J, Launey Y, et al：Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis：a multicenter randomized control trial. Intensive Care Med 41：975-984, 2015

22）Fujimori K, Tarasawa K, Fushimi K：Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score：a nationwide observational study. Ann Intensive Care 11：1-9, 2021

23）Nakamura Y, Kitamura T, Kiyomi F, et al：Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock：a propensity-matched cohort study. Critical Care 21：1-9, 2017

24）Ono S, Tsujimoto H, Matsumoto A, et al：Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber. Am J Surg 188：150-156, 2004

25）Ono S, Kimura A, Hiraki S, et al：Removal of increased circulating CD4＋CD25＋Foxp3＋ regulatory T cells in patients with septic shock using hemoperfusion with polymyxin B-immobilized fibers. Surgery 153：262-271, 2013

26）Tsujimoto H, Ono S, Hiraki S, et al：Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16＋CD14＋monocytes in patients with septic shock. J Endotoxin Res 10：229-237, 2004

27）Ono S, Kimura A, Hiraki S, et al：Removal of increased circulating CD4＋ CD25＋ Foxp3＋ regulatory T cells in patients with septic shock using hemoperfusion with polymyxin B-immobilized fibers. Surgery 153：262-271, 2013

28）木村暁史：重症敗血症時の免疫不全状態の病態解析とその対策に関する研究：免疫担当細胞に対するPMX-DHPの効果に着目して．大学評価・学位授与機構：2015

29）Hotchkiss RS, Colston E, Yende S, et al：Immune checkpoint inhibition in sepsis：a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Med 45：1360-1371, 2019